Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 28

Sort by

Sort Order Select

Journal Articles

Safety and efficacy of CPX-351 in younger patients (<60 years old) with secondary acute myeloid leukemia

Amanda Przespolewski, Aaron D. Goldberg, Chetasi Talati, Salman Fazal, Pankit Vachhani, Srinivasa R. Sanikommu, Swapna Thota, Julian Waksal, Brian Ball, Christopher Famulare, Maximilian Stahl, Jeffrey Baron, Elizabeth A. Griffiths, James E. Thompson, Kendra Sweet, Eunice S. Wang

Blood (2023) 141 (12): 1489–1493.

https://doi.org/10.1182/blood.2022016678

Published: 2023

Includes: Supplemental data

Journal Articles

Gemtuzumab Ozogamicin Plus Standard Induction Chemotherapy Improves Outcomes in Intermediate Risk Cytogenetic Acute Myeloid Leukemia

Hassan Awada, Mina Abdelmalek, Tara L. Cronin, Jeffrey Baron, Zakariya Kashour, Farhan Azad, Muhammad Salman Faisal, Mark G. Faber, Arya Roy, Ashish Gupta, Matthew Gravina, Sheeba Ba Aqeel, Alankrita Taneja, Pamela J. Sung, Steven D. Green, Amanda Przespolewski, James E. Thompson, Elizabeth A. Griffiths, Eunice S. Wang

Blood (2022) 140 (Supplement 1): 135–136.

https://doi.org/10.1182/blood-2022-168482

Published: 2022

Journal Articles

Impact of Race on the Mortality of Thrombotic Thrombocytopenic Purpura in the United States: A Population Study

Arya Mariam Roy, Aravind Mohanakumar Warrier, Hassan Awada, Sheeba Ba Aqeel, Karan Jatwani, Alankrita Taneja, Amanda Przespolewski

Blood (2022) 140 (Supplement 1): 5658–5659.

https://doi.org/10.1182/blood-2022-168331

Published: 2022

Journal Articles

Evorpacept (ALX148), a CD47-Blocking Myeloid Checkpoint Inhibitor, in Combination with Azacitidine and Venetoclax in Patients with Acute Myeloid Leukemia (ASPEN-05): Results from Phase 1a Dose Escalation Part

Guillermo Garcia-Manero, Amanda Przespolewski, Yasmin Abaza, Michael Byrne, Abraham P. Fong, Feng Jin, Alison J. Forgie, Athanasios C. Tsiatis, Shanhong Guan, Harry P. Erba

Blood (2022) 140 (Supplement 1): 9046–9047.

https://doi.org/10.1182/blood-2022-157606

Published: 2022

Journal Articles

Impact of Therapy on the Anamnestic Response to Seasonal Influenza Vaccination in Patients with Myeloid Malignancies

Kyle R Wiatrowski, Pragya Srivastava, Alan Hutson, Hana Golding, Surender Khurana, Lisa King, Jody Manischewitz, Molly Sheehan, Pankit Vachhani, Amanda Przespolewski, James E. Thompson, Eunice S. Wang, Michael J Nemeth, Elizabeth A. Griffiths

Blood (2022) 140 (Supplement 1): 315–316.

https://doi.org/10.1182/blood-2022-162720

Published: 2022

Journal Articles

Phase 1b Trial of Anti-Immunoglobulin-like Transcript 3 Monoclonal Antibody MK-0482 Monotherapy in Relapsed/Refractory Acute Myeloid Leukemia and Chronic Myelomonocytic Leukemia

Ghayas C. Issa, David Lavie, Amanda Przespolewski, Suraj Konnath George, Mo Huang, Mei Chen

Blood (2022) 140 (Supplement 1): 11759–11760.

https://doi.org/10.1182/blood-2022-169227

Published: 2022

Journal Articles

MRD Status and ELN 2022 Predicts for Outcomes of Venetoclax + Hypomethylating Therapy in AML: Single-Center Real-World Analysis

Mark G. Faber, Jeffrey Baron, Han Yu, Hassan Awada, Tara L. Cronin, James E. Thompson, Amanda Przespolewski, Steven D. Green, Pamela J. Sung, Elizabeth A. Griffiths, Eunice S. Wang

Blood (2022) 140 (Supplement 1): 9010–9012.

https://doi.org/10.1182/blood-2022-164707

Published: 2022

Journal Articles

Age, Sex and Self-Reported Race Differences in Immune Profiles of Hematologic Malignancy Patients

Megan M. Herr, Paul K. Wallace, Yali Zhang, George L. Chen, Sophia R. Balderman, Maureen Ross, Christine Ho, Jens Hillengass, Eunice S. Wang, Amanda Przespolewski, Elizabeth A. Griffiths, Pallawi Torka, Francisco J. Hernandez-Ilizaliturri, Paola Ghione, Philip L. McCarthy, Theresa E. Hahn

Blood (2021) 138 (Supplement 1): 4066.

https://doi.org/10.1182/blood-2021-150954

Published: 2021

Journal Articles

Phase 1b Trial of Talazoparib and Gemtuzumab Ozogamicin in Adult Patients with CD33+ Relapsed or Refractory Acute Myeloid Leukemia

Mahesh Swaminathan, Amanda Przespolewski, Elizabeth A. Griffiths, James E. Thompson, Amro Elshoury, Wendy Walinski, Meriem Said, Stephanie Halliwell, Claire Puff, Kristopher Attwood, Eunice S. Wang

Blood (2021) 138 (Supplement 1): 4435.

https://doi.org/10.1182/blood-2021-151636

Published: 2021

Journal Articles

Phase I Dose-Finding Study of Eltrombopag Following High Dose Cytarabine and Mitoxantrone Chemotherapy in Patients with Relapsed/Refractory Acute Myeloid Leukemia

Mahesh Swaminathan, Amanda Przespolewski, Elizabeth A. Griffiths, James E. Thompson, Amro Elshoury, Wendy Walinski, Eunice S. Wang

Blood (2021) 138 (Supplement 1): 4426.

https://doi.org/10.1182/blood-2021-152947

Published: 2021

Journal Articles

DNMT3A and TET2 mutant Clonal Hematopoiesis May Drive a Proinflammatory State and Predict Enhanced Response to Immune Checkpoint Inhibitors

Abhay Singh Singh, Nuria Mencia-Trinchant, Elizabeth A. Griffiths, Mahesh Swaminathan, Matthew Gravina, Rutaba Tajammal, Mark G. Faber, Marc S. Ernstoff, LunBiao Yan, Eti Sinha, Megan M. Herr, Duane C Hassane, Monica L. Guzman, Amanda Przespolewski, Eunice S. Wang, Swapna Thota

Blood (2021) 138 (Supplement 1): 4295.

https://doi.org/10.1182/blood-2021-150347

Published: 2021

Journal Articles

Gilteritinib Can be Safely Combined with Atezolizumab for the Treatment of Relapsed or Refractory FLT3 -Mutated AML: Results of a Phase 1 Study

Jessica K. Altman, Bhavana Bhatnagar, Sameem Abedin, Amanda Przespolewski, Prapti A. Patel, Gary J. Schiller, Stanley Gill, Dhruva Patel, Linyi Fan, Ramon V. Tiu, Stephen A. Strickland

Blood (2021) 138 (Supplement 1): 2343.

https://doi.org/10.1182/blood-2021-150707

Published: 2021

Journal Articles

Safety and Efficacy of CPX-351 in Younger Patients < 60 Years Old with Secondary Acute Myeloid Leukemia: An Updated Analysis

Amanda Przespolewski, Aaron D Goldberg, Chetasi Talati, Salman Fazal, Pankit Vachhani, Srinivasa Reddy R. Sanikommu, Swapna Thota, Julian Waksal, Brian Ball, Christopher Famulare, Maximilian Stahl, Zoe Mckinnell, Jeffrey Baron, Elizabeth A. Griffiths, James E. Thompson, Kendra Sweet, Eunice S. Wang

Blood (2021) 138 (Supplement 1): 1264.

https://doi.org/10.1182/blood-2021-153791

Published: 2021

Journal Articles

ASXL1 Mutation Is a Novel Risk Factor for Bleeding in Patients with Philadelphia-Negative Myeloproliferative Neoplasms (MPN)

Amro Elshoury, Han Yu, Wenyan Ji, James E. Thompson, Elizabeth A. Griffiths, Amanda Przespolewski, Steven Daniel Green, Pamela J. Sung, Sheeba baAqeel, Hassan Awada, Eunice S. Wang, Peter A. Kouides

Blood (2021) 138 (Supplement 1): 3637.

https://doi.org/10.1182/blood-2021-146384

Published: 2021

Journal Articles

Phase 1/1b Trial of Talazoparib and Gemtuzumab Ozogamicin in Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia

Amanda Przespolewski, DO, Elizabeth A. Griffiths, MD, James E. Thompson, MD, Amro Elshoury, MBBChir, Ashkan Emadi, MD, PhD, Vu H. Duong, MD, Sandrine Niyongere, MD, Wendy Walinski, Meriem Said, Stephanie Halliwell, Kemji Eke, Kristopher Attwood, PhD, Maria R. Baer, MD, Eunice S. Wang, MD

Blood (2020) 136 (Supplement 1): 20–21.

https://doi.org/10.1182/blood-2020-141736

Published: 2020

Journal Articles

Clonal Hematopoiesis in Patients Receiving Immune Checkpoint Inhibitor Therapy

Abhay Singh, MBBS,MPH, Nuria Mencia-Trinchant, PhD, Elizabeth A. Griffiths, MD, Matthew Gravina, MD, Rutaba Tajammal, MD, Mark G. Faber, DO, Annmarie Nowak, Marc S. Ernstoff, MD, LunBiao Yan, PhD, Megan M. Herr, PhD, Duane C. Hassane, PhD, Monica L. Guzman, PhD, Eunice S. Wang, MD, Amanda Przespolewski, DO, Swapna Thota, MD

Blood (2020) 136 (Supplement 1): 15–16.

https://doi.org/10.1182/blood-2020-141617

Published: 2020

Journal Articles

Benefits of a Pharmacist Led Oral Chemotherapy Monitoring Program for Patients with Chronic Myeloid Malignancies: A Patient Reported Outcome (PRO) Study

Jeffrey Baron, PharmD, Christina L. Lombardi, PharmD, Han Yu, PhD, Amanda Przespolewski, DO, Elizabeth A. Griffiths, MD, James E. Thompson, MD, Swapna Thota, MD, Eunice S. Wang, MD

Blood (2019) 134 (Supplement_1): 3501.

https://doi.org/10.1182/blood-2019-131629

Published: 2019

Journal Articles

Quantification of Humoral Immune Response to Influenza Vaccination in MDS

Pankit Vachhani, MD, Kyle Wiatrowski, Pragya Srivastava, PhD, Lisa King, Jody Manischewitz, Hana Golding, Heather L Bashaw, BA, Ava R. Dimitroff, Amanda Przespolewski, DO, James E. Thompson, MD, Swapna Thota, MD, Eunice S. Wang, MD, Michael J. Nemeth, PhD, Elizabeth A. Griffiths, MD

Blood (2019) 134 (Supplement_1): 4756.

https://doi.org/10.1182/blood-2019-126176

Published: 2019

Journal Articles

Cladribine, Cytarabine, Granulocyte Colony Stimulating Factor ± Mitoxantrone (CLAG ± M) Is Highly Effective Therapy for Secondary and Relapsed/Refractory Acute Myeloid Leukemia

Amanda Przespolewski, DO, Craig W. Freyer, PharmD, Wenyan Ji, MA, Tara L. Cronin, BA, Swapna Thota, MD, Elizabeth A. Griffiths, MD, James E. Thompson, MD, Amro Elshoury, MBBChir, Jeffrey Baron, PharmD, Mark Walsh, PharmD, Eunice S. Wang, MD

Blood (2019) 134 (Supplement_1): 1361.

https://doi.org/10.1182/blood-2019-130582

Published: 2019

Journal Articles

Outcomes of Venetoclax-Based Regimens Compared with Hypomethylating Agents (HMA) Alone or 7+3 in Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia (AML): A Single Center Retrospective Analysis

Manu Pandey, MBBS, Mahesh Swaminathan, MBBS, Elizabeth A. Griffiths, MD, James E. Thompson, MD, Amanda Przespolewski, DO, Swapna Thota, MD, Jeffrey Baron, PharmD, Tara L. Cronin, BA, Eunice S. Wang, MD

Blood (2019) 134 (Supplement_1): 3866.

https://doi.org/10.1182/blood-2019-132123

Published: 2019

NARROW

Safety and efficacy of CPX-351 in younger patients (<60 years old) with secondary acute myeloid leukemia

Gemtuzumab Ozogamicin Plus Standard Induction Chemotherapy Improves Outcomes in Intermediate Risk Cytogenetic Acute Myeloid Leukemia

Impact of Race on the Mortality of Thrombotic Thrombocytopenic Purpura in the United States: A Population Study

Evorpacept (ALX148), a CD47-Blocking Myeloid Checkpoint Inhibitor, in Combination with Azacitidine and Venetoclax in Patients with Acute Myeloid Leukemia (ASPEN-05): Results from Phase 1a Dose Escalation Part

Impact of Therapy on the Anamnestic Response to Seasonal Influenza Vaccination in Patients with Myeloid Malignancies

Phase 1b Trial of Anti-Immunoglobulin-like Transcript 3 Monoclonal Antibody MK-0482 Monotherapy in Relapsed/Refractory Acute Myeloid Leukemia and Chronic Myelomonocytic Leukemia

MRD Status and ELN 2022 Predicts for Outcomes of Venetoclax + Hypomethylating Therapy in AML: Single-Center Real-World Analysis

Age, Sex and Self-Reported Race Differences in Immune Profiles of Hematologic Malignancy Patients

Phase 1b Trial of Talazoparib and Gemtuzumab Ozogamicin in Adult Patients with CD33+ Relapsed or Refractory Acute Myeloid Leukemia

Phase I Dose-Finding Study of Eltrombopag Following High Dose Cytarabine and Mitoxantrone Chemotherapy in Patients with Relapsed/Refractory Acute Myeloid Leukemia

DNMT3A and TET2 mutant Clonal Hematopoiesis May Drive a Proinflammatory State and Predict Enhanced Response to Immune Checkpoint Inhibitors

Gilteritinib Can be Safely Combined with Atezolizumab for the Treatment of Relapsed or Refractory FLT3 -Mutated AML: Results of a Phase 1 Study

Safety and Efficacy of CPX-351 in Younger Patients < 60 Years Old with Secondary Acute Myeloid Leukemia: An Updated Analysis

ASXL1 Mutation Is a Novel Risk Factor for Bleeding in Patients with Philadelphia-Negative Myeloproliferative Neoplasms (MPN)

Phase 1/1b Trial of Talazoparib and Gemtuzumab Ozogamicin in Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia

Clonal Hematopoiesis in Patients Receiving Immune Checkpoint Inhibitor Therapy

Benefits of a Pharmacist Led Oral Chemotherapy Monitoring Program for Patients with Chronic Myeloid Malignancies: A Patient Reported Outcome (PRO) Study

Quantification of Humoral Immune Response to Influenza Vaccination in MDS

Cladribine, Cytarabine, Granulocyte Colony Stimulating Factor ± Mitoxantrone (CLAG ± M) Is Highly Effective Therapy for Secondary and Relapsed/Refractory Acute Myeloid Leukemia

Outcomes of Venetoclax-Based Regimens Compared with Hypomethylating Agents (HMA) Alone or 7+3 in Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia (AML): A Single Center Retrospective Analysis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only